 Lead researcher Dr Lennard Lee, of Birmingham University, said: 'There is strong evidence emerging across the world that this approach of using prophylactic antibody therapies in combination with vaccination is a revolutionary approach to safeguard the most vulnerable patients this winter. 'The science and data suggest that it would be a successful approach for many cancer and immunocompromised patients at the highest level of risk'. The systemic review was commissioned by the All-Party Parliamentary Group for Vulnerable Groups to Pandemics. Evusheld, made by AstraZeneca in the UK, is prescribed to millions in 32 countr){kind=link}
Research suggests the drug, called Evusheld, would be 88% effective at preventing intensive care admission for people with weakened immune systems still shielding from Covid because vaccines don’t work for them.
A drug desperately sought after by Brits still at high risk from Covid-19 has been proven to save lives – despite the Government refusing to fund it on the NHS.
A global review of Evusheld suggests it would be 86% effective at protecting half a million immunosuppressed Brits currently still shielding because vaccines do not work for them.
Birmingham University and King’s College London have reviewed 17 trials of antibody boosting treatments including 25,000 participants.
It concluded they are 88% effective at preventing intensive care admission, 69% effective at preventing a hospital admission and 40% effective at preventing infection.